Christine H Chung

27PUBLICATIONS
178CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Virtual and mixed realityTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|May 08, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

|Mar 20, 2026
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.

Alexander T Pearson, Jameel Muzaffar, Kedar Kirtane

|Dec 10, 2025
Durable Complete Response of a Delta-Like Ligand 3 Expressing Head and Neck Neuroendocrine Carcinoma to Tarlatamab.

Kedar Kirtane, Sonam Puri, Christine H Chung

|Oct 21, 2025
Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.

Ritu Chaudhary, Graydon Moorhead, Robin Park

|Sep 04, 2025
Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial.

Robin Park, Fahad Rind, Tyler Kristoff

|Aug 25, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Robert L Ferris, Rom S Leidner, Christine H Chung

Pageof 5

Frequent Collaborators

8 joint publications

Nabil F Saba

6 joint publications

Kedar Kirtane

6 joint publications

Robbert J C Slebos

5 joint publications

Ritu Chaudhary